VNRX Stock Catalyst: VolitionRX LTD Announced Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

Aug 26, 2026 · 7:08am ET

The validation was announced on a recent press release.

Max move

+67.8%

High of day $0.71

Sparker timei

7:08am ET

VNRX · Aug 26, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

VolitionRX LTD (NYSE: VNRX), a healthcare company specializing in medical devices, announced the clinical validation of its Nu.Q® NETs biomarker for sepsis detection. The announcement was made via a press release.

The validation process confirmed the biomarker's effectiveness in identifying sepsis, a critical condition. No financial figures or share considerations were disclosed in the announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time VNRX sparks.

Download Sniper App →

Catch the next VNRX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →